New insights into huperzine A for the treatment of Alzheimer's disease

Acta Pharmacologica Sinica

Volumn 33, Issue 9, 2012, Pages 1170-1175

  Zhang, Hai Yan ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

acetylcholinesterase; Alzheimer's disease; controlled release; huperzine A; mitochondrion

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; HUPERZINE A; MESSENGER RNA; NERVE GROWTH FACTOR; NEUROTROPHIN RECEPTOR P75; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTHRALGIA; BRADYCARDIA; CHINA; CHOLINERGIC TRANSMISSION; CIRCADIAN RHYTHM; CONTROLLED DRUG RELEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; ENERGY; HUMAN; HYPERTENSION; INHIBITION KINETICS; MEMORY DISORDER; MITOCHONDRION; MUSCLE CRAMP; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN SECRETION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SLOW WAVE SLEEP; SUSTAINED RELEASE FORMULATION; TACHYCARDIA; UNITED STATES; UNPLEASANT DREAM;

ALKALOIDS; ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; DRUG DELIVERY SYSTEMS; DRUGS, CHINESE HERBAL; HUMANS; LYCOPODIUM; MITOCHONDRIA; NEUROPROTECTIVE AGENTS; SESQUITERPENES;

EID: 84865957834     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.128     Document Type: Review

References (59)

1. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012; 148: 1204-22.
2. Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 2006; 27: 1-26. (Pubitemid 43051942)
3. Zhang HY, Tang XC. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci 2006; 27: 619-25. (Pubitemid 44738090)
4. Domer FR, Schueler FW. Investigations of the amnesic properties of scopolamine and related compounds. Arch Int Pharmacodyn Ther 1960; 127: 449-58.
5. Drachman DA, Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974; 30: 113-21.
6. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-14.
7. Sunderland T, Tariot PN, Weingartner H, Murphy DL, Newhouse PA, Mueller EA, et al. Pharmacologic modelling of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1986; 10: 599-610.
8. Knipper M, da Penha Berzaghi M, Blochl A, Breer H, Thoenen H, Lindholm D. Positive feedback between acetylcholine and the neurotrophins nerve growth factor and brain-derived neurotrophic factor in the rat hippocampus. Eur J Neurosci 1994; 6: 668-71. (Pubitemid 24106852)
9. Fisher A, Michaelson DM, Brandeis R, Haring R, Chapman S, Pittel Z. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives. Ann N Y Acad Sci 2000; 920: 315-20. (Pubitemid 32056587)
10. Rossner S, Ueberham U, Schliebs R, Perez-Polo JR, Bigl V. The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog Neurobiol 1998; 56: 541-69. (Pubitemid 28407571)
11. Conejero-Goldberg C, Davies P, Ulloa L. Alpha7 nicotinic acetylcholine receptor: a link between inflammation and neurodegeneration. Neurosci Biobehav Rev 2008; 32: 693-706.
12. Tang LL, Wang R, Tang XC. Effects of huperzine A on secretion of nerve growth factor in cultured rat cortical astrocytes and neurite outgrowth in rat PC12 cells. Acta Pharmacol Sin 2005; 26: 673-8. (Pubitemid 40806555)
13. Zhang HY, Yan H, Tang XC. Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-alpha in intracerebroventricular beta-amyloid-(1-40) infused rats and human embryonic kidney 293 Swedish mutant cells. Neurosci Lett 2004; 360: 21-4. (Pubitemid 38471978)
14. Tang LL, Wang R, Tang XC. Huperzine A protects SHSY5Y neuroblastoma cells against oxidative stress damage via nerve growth factor production. Eur J Pharmacol 2005; 519: 9-15. (Pubitemid 43181158)
15. Wang ZF, Tang LL, Yan H, Wang YJ, Tang XC. Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice. Pharmacol Biochem Behav 2006; 83: 603-11. (Pubitemid 43817131)
16. Yan H, Zhang HY, Tang XC. Involvement of M1-muscarinic acetylcholine receptors, protein kinase C and mitogen-activated protein kinase in the effect of huperzine A on secretory amyloid precursor protein-alpha. Neuroreport 2007; 18: 689-92. (Pubitemid 46608516)
17. Wang ZF, Tang XC. Huperzine A protects C6 rat glioma cells against oxygen-glucose deprivation-induced injury. FEBS Lett 2007; 581: 596-602. (Pubitemid 46216285)
18. Wang ZF, Wang J, Zhang HY, Tang XC. Huperzine A exhibits antiinflammatory and neuroprotective effects in a rat model of transient focal cerebral ischemia. J Neurochem 2008; 106: 1594-603.
19. Wang J, Zhang HY, Tang XC. Huperzine A improves chronic inflamma tion and cognitive decline in rats with cerebral hypoperfusion. J Neurosci Res 2010; 88: 807-15.
20. Fayuk D, Yakel JL. Regulation of nicotinic acetylcholine receptor channel function by acetylcholinesterase inhibitors in rat hippocampal CA1 interneurons. Mol Pharmacol 2004; 66: 658-66. (Pubitemid 39329265)
21. Shigeta K, Ootaki K, Tatemoto H, Nakanishi T, Inada A, Muto N. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by a Coptidis Rhizoma extract and protoberberine alkaloids. Biosci Biotechnol Biochem 2002; 66: 2491-4. (Pubitemid 39251193)
22. Giacobini E, Mori F, Lai CC. The effect of cholinesterase inhibitors on the secretion of APPS from rat brain cortex. Ann N Y Acad Sci 1996; 777: 393-8. (Pubitemid 26149220)
23. Mori F, Lai CC, Fusi F, Giacobini E. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport 1995; 6: 633-6.
24. Frey TG, Mannella CA. The internal structure of mitochondria. Trends Biochem Sci 2000; 25: 319-24.
25. Silva DF, Esteves AR, Oliveira CR, Cardoso SM. Mitochondria: the common upstream driver of amyloid-beta and tau pathology in Alzheimer's disease. Curr Alzheimer Res 2011; 8: 563-72.
26. Gao X, Tang XC. Huperzine A attenuates mitochondrial dysfunction in beta-amyloid-treated PC12 cells by reducing oxygen free radicals accumulation and improving mitochondrial energy metabolism. J Neurosci Res 2006; 83: 1048-57.
27. Gao X, Zheng CY, Yang L, Tang XC, Zhang HY. Huperzine A protects isolated rat brain mitochondria against beta-amyloid peptide. Free Radic Biol Med 2009; 46: 1454-62.
28. Yang L, Ye CY, Huang XT, Tang XC, Zhang HY. Decreased accumulation of subcellular amyloid-beta with improved mitochondrial function mediates the neuroprotective effect of huperzine A. J Alzheimers Dis 2012; 31: 131-42.
29. Zheng CY, Zhang HY, Tang XC. Huperzine A attenuates mitochondrial dysfunction after middle cerebral artery occlusion in rats. J Neurosci Res 2008; 86: 2432-40.
30. Xiao XQ, Zhang HY, Tang XC. Huperzine A attenuates amyloid betapeptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J Neurosci Res 2002; 67: 30-6.
31. Wang R, Zhang HY, Tang XC. Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid protein-(1-40) in rat. Eur J Pharmacol 2001; 421: 149-56. (Pubitemid 32539415)
32. Xiao XQ, Wang R, Han YF, Tang XC. Protective effects of huperzine A on beta-amyloid(25-35) induced oxidative injury in rat pheochromocytoma cells. Neurosci Lett 2000; 286: 155-8. (Pubitemid 30314633)
33. Xiao XQ, Wang R, Tang XC. Huperzine A and tacrine attenuate betaamyloid peptide-induced oxidative injury. J Neurosci Res 2000; 61: 564-9.
34. Xiao XQ, Yang JW, Tang XC. Huperzine A protects rat pheochromocytoma cells against hydrogen peroxide-induced injury. Neurosci Lett 1999; 275: 73-6. (Pubitemid 29502539)
35. Wang LM, Han YF, Tang XC. Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. Eur J Pharmacol 2000; 398: 65-72. (Pubitemid 30336678)
36. Shang YZ, Ye JW, Tang XC. Improving effects of huperzine A on abnormal lipid peroxidation and superoxide dismutase in aged rats. Zhongguo Yao Li Xue Bao 1999; 20: 824-8.
37. Zhang HY, Tang XC. Huperzine A attenuates the neurotoxic effect of staurosporine in primary rat cortical neurons. Neurosci Lett 2003; 340: 91-4. (Pubitemid 36369282)
38. Zhou J, Tang XC. Huperzine A attenuates apoptosis and mitochondriadependent caspase-3 in rat cortical neurons. FEBS Lett 2002; 526: 21-5. (Pubitemid 35245685)
39. Wang R, Xiao XQ, Tang XC. Huperzine A attenuates hydrogen peroxideinduced apoptosis by regulating expression of apoptosis-related genes in rat PC12 cells. Neuroreport 2001; 12: 2629-34. (Pubitemid 32803190)
40. Tillement L, Lecanu L, Papadopoulos V. Alzheimer's disease: effects of beta-amyloid on mitochondria. Mitochondrion 2011; 11: 13-21.
41. Hansson Petersen CA, Alikhani N, Behbahani H, Wiehager B, Pavlov PF, Alafuzoff I, et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci U S A 2008; 105: 13145-50.
42. Singh P, Suman S, Chandna S, Das TK. Possible role of amyloid-beta, adenine nucleotide translocase and cyclophilin-D interaction in mitochondrial dysfunction of Alzheimer's disease. Bioinformation 2009; 3: 440-5.
43. Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 2004; 304: 448-52. (Pubitemid 38495942)
44. Murakami Y, Ohsawa I, Kasahara T, Ohta S. Cytoprotective role of mitochondrial amyloid beta peptide-binding alcohol dehydrogenase against a cytotoxic aldehyde. Neurobiol Aging 2009; 30: 325-9.
45. Culman J, Zhao Y, Gohlke P, Herdegen T. PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol Sci 2007; 28: 244-9. (Pubitemid 46661003)
46. Fong WH, Tsai HD, Chen YC, Wu JS, Lin TN. Anti-apoptotic actions of PPAR-gamma against ischemic stroke. Mol Neurobiol 2010; 41: 180-6.
47. Zhao X, Strong R, Zhang J, Sun G, Tsien JZ, Cui Z, et al. Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia. J Neurosci 2009; 29: 6186-95.
48. Wang Y, Yang YS, Tang XC, Zhang HY. T33, a novel peroxisome proliferator-activated receptor gamma/alpha agonist, exerts neuroprotective action via its anti-inflammatory activities. Acta Pharmacol Sin 2011; 32: 1100-8.
49. Ferreiro E, Baldeiras I, Ferreira IL, Costa RO, Rego AC, Pereira CF, et al. Mitochondrial-and endoplasmic reticulum-associated oxidative stress in Alzheimer's disease: from pathogenesis to biomarkers. Int J Cell Biol 2012; 2012: 735206.
50. Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 2011; 76: 1389-94.
51. Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. J Neural Transm 2009; 116: 457-65.
52. Chu D, Liu W, Li Y, Li P, Gu J, Liu K. Pharmacokinetics of huperzine A in dogs following single intravenous and oral administrations. Planta Med 2006; 72: 552-5. (Pubitemid 43844684)
53. Wang Q, Chen G. Pharmacokinetic behavior of huperzine A in plasma and cerebrospinal fluid after intranasal administration in rats. Biopharm Drug Dispos 2009; 30: 551-5.
54. Fu X, Ping Q, Gao Y. Effects of formulation factors on encapsulation efficiency and release behaviour in vitro of huperzine A-PLGA microspheres. J Microencapsul 2005; 22: 705-14. (Pubitemid 43158192)
55. Gao P, Ding P, Xu H, Yuan Z, Chen D, Wei J, et al. In vitro and in vivo characterization of huperzine a loaded microspheres made from endgroup uncapped poly(d,l-lactide acid) and poly(d,l-lactide-co-glycolide acid). Chem Pharm Bull (Tokyo) 2006; 54: 89-93. (Pubitemid 43036756)
56. Liu WH, Song JL, Liu K, Chu DF, Li YX. Preparation and in vitro and in vivo release studies of Huperzine A loaded microspheres for the treatment of Alzheimer's disease. J Control Release 2005; 107: 417-27. (Pubitemid 41393352)
57. Nieoullon A, Bentue-Ferrer D, Bordet R, Tsolaki M, Forstl H. Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine. Curr Med Res Opin 2008; 24: 3357-67.
58. Gais S, Born J. Low acetylcholine during slow-wave sleep is critical for declarative memory consolidation. Proc Natl Acad Sci U S A 2004; 101: 2140-4. (Pubitemid 38229028)
59. Roberts SF, Fischhoff MA, Sakowski SA, Feldman EL. Perspective: Transforming science into medicine: how clinician-scientists can build bridges across research's "valley of death". Acad Med 2012; 87: 266-70.